[go: up one dir, main page]

DK3543240T3 - URAT1-inhibitor og anvendelse deraf - Google Patents

URAT1-inhibitor og anvendelse deraf Download PDF

Info

Publication number
DK3543240T3
DK3543240T3 DK17872538.8T DK17872538T DK3543240T3 DK 3543240 T3 DK3543240 T3 DK 3543240T3 DK 17872538 T DK17872538 T DK 17872538T DK 3543240 T3 DK3543240 T3 DK 3543240T3
Authority
DK
Denmark
Prior art keywords
urat1 inhibitor
urat1
inhibitor
Prior art date
Application number
DK17872538.8T
Other languages
English (en)
Inventor
Dongfang Shi
Changjin Fu
Xi Cheng
Jianghua Zhu
Jie Gu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62172162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3543240(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co Ltd filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Priority claimed from PCT/CN2017/111013 external-priority patent/WO2018090921A1/zh
Application granted granted Critical
Publication of DK3543240T3 publication Critical patent/DK3543240T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK17872538.8T 2016-11-16 2017-11-15 URAT1-inhibitor og anvendelse deraf DK3543240T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611008935 2016-11-16
CN201711115037.9A CN108084186B (zh) 2016-11-16 2017-11-13 Urat1抑制剂及其应用
PCT/CN2017/111013 WO2018090921A1 (zh) 2016-11-16 2017-11-15 Urat1抑制剂及其应用

Publications (1)

Publication Number Publication Date
DK3543240T3 true DK3543240T3 (da) 2022-10-10

Family

ID=62172162

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17872538.8T DK3543240T3 (da) 2016-11-16 2017-11-15 URAT1-inhibitor og anvendelse deraf

Country Status (18)

Country Link
US (2) US10875865B2 (da)
EP (1) EP3543240B1 (da)
JP (1) JP6925054B2 (da)
KR (1) KR102263441B1 (da)
CN (1) CN108084186B (da)
AU (1) AU2017360465B2 (da)
CA (1) CA3043942C (da)
DK (1) DK3543240T3 (da)
ES (1) ES2923177T3 (da)
HR (1) HRP20221151T1 (da)
HU (1) HUE059778T2 (da)
IL (1) IL266587B2 (da)
MX (1) MX2019005565A (da)
MY (1) MY197564A (da)
PL (1) PL3543240T3 (da)
PT (1) PT3543240T (da)
RS (1) RS63572B1 (da)
TW (1) TWI668213B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066680C (en) * 2017-05-26 2022-04-12 Dongfang Shi Urat1 inhibitor for increasing uric acid excretion
CN117586272A (zh) * 2018-01-19 2024-02-23 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用
CN108623586B (zh) * 2018-07-16 2021-03-16 广东工业大学 一种咪唑并含氮杂环类化合物的合成方法与应用
CN109432079B (zh) * 2018-09-07 2021-06-22 江苏康缘药业股份有限公司 一种化合物在制备用于痛风的药物中的应用
CN111763180B (zh) * 2019-04-02 2023-06-09 中国医学科学院药物研究所 苯并氮杂环类化合物及其制法和药物用途
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111533718B (zh) * 2020-05-12 2022-05-17 浙江海洲制药有限公司 一种制备苯溴马隆的方法
CN112250688B (zh) * 2020-10-15 2022-11-04 天津科技大学 一类7-氮杂苯并呋喃衍生物及其在抗肿瘤药物中的应用
CN112877295A (zh) * 2021-02-26 2021-06-01 华南理工大学 一种urat1抑制剂体外活性筛选的细胞模型及其构建方法与筛选方法
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout
CN116189808A (zh) * 2023-01-17 2023-05-30 中国海洋大学 一种hURAT1抑制剂的筛选方法、筛选的化合物及其应用
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117128A (en) * 1976-08-03 1978-09-26 Smithkline Corporation Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2502622A1 (fr) * 1981-03-25 1982-10-01 Synthelabo Derives d'imidazo (1,2-a) pyrimidines, leur preparation et leur application en therapeutique
US5175184A (en) * 1982-10-19 1992-12-29 Kotobuki Seiyaku Company Limited Benzothiophene derivatives and antihyperuricemia thereof
JPS5973579A (ja) * 1982-10-19 1984-04-25 Kotobuki Seiyaku Kk ベンゾフラン又はベンゾチオフェン誘導体,この化合物を有効成分とする尿酸排泄剤及びその製造方法
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB8820231D0 (en) * 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
WO1999058519A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
KR20040030818A (ko) * 2001-07-20 2004-04-09 카로 바이오 아베 심방 세동의 치료에 있어서의 벤조 퓨란 및 이들의 용도
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CA2718709C (en) 2008-03-31 2016-08-09 C & C Research Laboratories Heterocyclic derivatives
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
US20150216867A1 (en) * 2012-09-25 2015-08-06 Novartis Ag Compounds for use in gastric complication
CA2971125C (en) * 2014-12-29 2024-05-21 Nippon Chemiphar Co., Ltd. Urat1 inhibitor
SG11201706869XA (en) * 2015-03-24 2017-09-28 Shanghai Yingli Pharm Co Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
CN106065010B (zh) * 2015-04-23 2019-01-01 镇江新元素医药科技有限公司 用于治疗或预防高尿酸血症或痛风的化合物
HUE051448T2 (hu) * 2015-09-10 2021-03-01 Jiangsu Atom Bioscience Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
CN108727267B (zh) * 2017-05-26 2022-05-13 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用

Also Published As

Publication number Publication date
IL266587A (en) 2019-07-31
KR102263441B1 (ko) 2021-06-09
PT3543240T (pt) 2022-08-25
AU2017360465A1 (en) 2019-06-06
MX2019005565A (es) 2019-10-30
ES2923177T3 (es) 2022-09-26
PL3543240T3 (pl) 2022-10-24
US20200062763A1 (en) 2020-02-27
KR20190077083A (ko) 2019-07-02
CA3043942C (en) 2021-11-02
EP3543240A4 (en) 2020-05-06
EP3543240A1 (en) 2019-09-25
US10875865B2 (en) 2020-12-29
TWI668213B (zh) 2019-08-11
RS63572B1 (sr) 2022-10-31
CA3043942A1 (en) 2018-05-24
TW201819364A (zh) 2018-06-01
CN108084186B (zh) 2021-06-25
HRP20221151T1 (hr) 2022-11-25
AU2017360465B2 (en) 2021-02-04
USRE50083E1 (en) 2024-08-20
MY197564A (en) 2023-06-23
JP6925054B2 (ja) 2021-08-25
IL266587B2 (en) 2023-06-01
HUE059778T2 (hu) 2022-12-28
JP2020503263A (ja) 2020-01-30
CN108084186A (zh) 2018-05-29
EP3543240B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3227342T4 (da) Proteinøs heterodimer og anvendelse deraf
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3430129T3 (da) Kolonidannende medium og anvendelse deraf
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3447056T3 (da) Multikinasehæmmerforbindelse, krystalform og anvendelse deraf
DK3426243T3 (da) 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3142659T3 (da) Hiv-1 proteasehæmmere og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3166945T3 (da) Hidtil ukendte triazolopyrimidinon- eller triazolopyridinderivater og anvendelse deraf